459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC

• Matthew Hellmann,
• Ying Cheng,
• Toshiaki Takahashi,
• Gilberto de Castro,
• M Catherine Pietanza,
• James Chih-Hsin Yang,
• Byoung Cho,
• Rosalyn Juergens,
• Mustafa Erman,
• Jessica Bauman,
• Paul Schwarzenberger,
• Pingye Zhang

Affiliations

Matthew Hellmann

Aff1 grid.51462.340000000121719952Memorial Sloan Kettering Cancer Center New York NY USA

Ying Cheng

Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Toshiaki Takahashi

Department of Neurology and Division of Clinical Research, National Hospital Organization Nishitaga National Hospital, Sendai, Japan

Gilberto de Castro

1Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil

M Catherine Pietanza

18Merck and Co., Inc., Kenilworth, NJ, USA

James Chih-Hsin Yang

10National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei City, Taiwan, Province of China

Byoung Cho

2Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

Rosalyn Juergens

3McMaster University, Juravinski Cancer Centre, Hamilton, ON, Canada

Mustafa Erman

6Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey

Jessica Bauman

7Fox Chase Cancer Center, Philadelphia, PA, USA

Paul Schwarzenberger

9Merck and Co., Inc., Kenilworth, NJ, USA

Pingye Zhang

9Merck and Co., Inc., Kenilworth, NJ, USA